[Comparison of next-generation flow cytometry and next-generation sequencing in the assessment of minimal residual disease in multiple myeloma]

Zhonghua Xue Ye Xue Za Zhi. 2023 Apr 14;44(4):328-332. doi: 10.3760/cma.j.issn.0253-2727.2023.04.011.

[Article in Chinese]

Authors

Q Q Wang¹, L Yao¹, M Q Zhu¹, L Z Yan¹, S Jin¹, J J Shang¹, X L Shi¹, Y Y Zhai¹, S Yan¹, W Q Yao¹, H Y You¹, D P Wu¹, C C Fu¹

Affiliation

¹ Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, NHC Key Laboratory of Thrombosis and Hemostasis, the First Affiliated Hospital of Soochow University, Suzhou 215000, China.

PMID: 37357003
PMCID: PMC10282880
DOI: 10.3760/cma.j.issn.0253-2727.2023.04.011

No abstract available

MeSH terms

Flow Cytometry
High-Throughput Nucleotide Sequencing
Humans
Multiple Myeloma* / genetics
Neoplasm, Residual / diagnosis

Grants and funding

基金项目：国家血液系统疾病临床医学研究中心转化研究课题（2020ZKPB01）；苏州市2021年度第十二批科技发展计划医疗器械与新医药医工结合协同创新研究项目（SLJ2021004）